From the Guidelines
CRMP5 (Collapsin Response Mediator Protein 5) antibodies are onconeural antibodies that target intracellular antigens and are associated with paraneoplastic neurological syndromes (PNS), particularly small cell lung cancer (SCLC) and other tumors. These antibodies are considered markers for the immune-mediated process but are not likely to be pathogenic, with T cell cytotoxicity being the proposed pathogenic mechanism 1. The presence of CRMP5 antibodies can be detected through commercial assays for immunoblotting with recombinant proteins, and their detection is crucial for diagnosing PNS and guiding treatment decisions.
Key Points
- CRMP5 antibodies are associated with PNS, particularly SCLC and other tumors
- They target intracellular antigens and are considered markers for the immune-mediated process
- T cell cytotoxicity is the proposed pathogenic mechanism
- Detection of CRMP5 antibodies is crucial for diagnosing PNS and guiding treatment decisions
- Treatment often involves immunosuppression and symptomatic management, with a focus on tumor treatment
Diagnosis and Treatment
Testing for CRMP5 antibodies typically involves indirect immunohistochemistry or immunofluorescence on fixed and/or frozen rat brain tissue, followed by confirmation with more specific techniques such as commercial assays for immunoblotting with recombinant proteins 1. Treatment for PNS associated with CRMP5 antibodies often involves immunosuppression and symptomatic management, with a focus on tumor treatment. It's essential to screen for underlying malignancies, particularly SCLC, as PNS can be paraneoplastic in a significant proportion of cases.
Antibody Detection
The gold standard for detecting CRMP5 antibodies is an assay based on mammalian cells transiently transfected with the antigen of interest and incubated with the patient's serum or CSF 1. This technique, commonly named a cell-based or cell binding assay, is sensitive and specific, as only one antigenic target is overexpressed in these cells.
From the Research
CRMP5 Antibodies
- CRMP5 (Collapsin Response Mediator Protein 5) antibodies are not directly mentioned in the provided studies 2, 3, 4, 5, 6
- The studies primarily focus on neuromyelitis optica spectrum disorders (NMOSD) and the use of monoclonal antibodies as a treatment option
- Some of the studies discuss the efficacy and safety of monoclonal antibodies targeting specific proteins, such as aquaporin-4 (AQP4) 3, 5, 6
- However, none of the studies provide information on CRMP5 antibodies, suggesting that there may be limited research or evidence available on this specific topic
Related Research
- The provided studies do discuss the use of monoclonal antibodies in the treatment of NMOSD, which may be relevant to understanding the broader context of antibody research in this field 2, 3, 4, 5, 6
- However, without direct evidence or research on CRMP5 antibodies, it is difficult to draw conclusions or make connections to the existing body of research on NMOSD and monoclonal antibodies